Let’s talk about risk and the big picture. This is an opportune time as the huge risk presented by the COVID-19 outbreak has finally subsided thanks to the ongoing vaccination program. COVID is leaving behind an economy that was forced to shut down amid a massive expansion backed by deregulation policies a year ago. While the new Biden Administration has been busy reversing many Trump policies, the economy is recovering, at least for now. This puts us at risk. The period of economic growth and recovery is a forgiving time to invest in risk, as general economic growth tends to lift everything. Two JPMorgan strategists recently intervened, supporting the view that the fundamentals of the market are still solid and that the small and medium-sized industry will continue to rise. First, quantitative strategist Dubravko Lakos-Bujas wrote in general conditions: “While the final technical sales and short print have received a lot of attention, we believe in positive macro setup, improved fundamentals and the COVID-19 outlook, the strength of the US consumer and reflation theme, continues to be the bigger forces in the game. Not only does this drive equity further up, but it continues to be conducive to the continuing rotation towards economic reopening… ”Based on this, Eduardo Lecubarr, head of the Small / Medium Strategy team, said for investors, especially stocks seeing lower value opportunities. “If you are willing to go against the grains, we stick to our view that 2021 will be a stockists’ paradise with big money making opportunities … In January, many macro indicators fell, but SMid-Caps and stocks in general continued to rise, “Lecubarr noted. And if you don’t mind looking at high risk, small and medium-sized stocks. If you are eyed, you will find yourself focused on penny stocks. The risk associated with these games scares weak hearts, as very real problems, such as weak foundations or overwhelming counterwinds, can be masked by low share prices. So how should investors approach a potential penny stock investment? Getting a tip from the analyst community. These experts bring to the table in-depth knowledge and important experiences about the industries they cover. With this in mind, according to Wall Street analysts, we used the TipRanks database to find a two-penny stock. Both stripes have a Strong Buy consensus and could rise by over 200% next year. CNS Pharmaceuticals (CNSP) We’ll start with CNS Pharmaceuticals, a biotech company focused on the treatment of glioblastomas, a class of aggressive tumors that attack the knit and spinal cord. While these cancers are rare, they are almost always terminal, and the CNS is working on a new treatment designed to more effectively cross the blood-brain barrier to attack the glioblastoma. Berubicin, the CNS ‘flagship candidate, is an anthracycline, a powerful class of chemotherapy drugs derived from Streptomyces bacterial strains and used to treat a wide variety of cancers. Berubicin is the first promising drug against glioblastoma cancers in this class. The drug candidate completed the Phase 1 clinical trial in which 44% of patients had clinical response. This number included a patient with a ‘Resistant Complete Response’ defined as a detectable cancer deficiency. Following the success of the Phase 1 trial, CNS applied for New Drug Research Purposes and received FDA approval. This gives the company the chance to run a Phase 2 study on adult patients, which is the next important step in drug development. The CNS plans to begin the mid-stage trial in 1Q21. Based on the company’s existence potential in glioblastoma and its $ 2.22 share price, several analysts now believe it’s time to buy. Among the bulls is Kumaraguru Raja, a 5-star analyst, who has risen on Brookline’s CNSP shares. Until now, the inability of anthracyclines to cross the blood brain barrier prevented their use in the treatment of brain cancers. Berubicin is the first anthracycline to cross the blood-brain barrier and reach brain tumors in adults… Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has the FDA definition of Orphan drug for the treatment of malignant gliomas. We model the approval of Berubicin for recurrent glioblastoma treatment in 2025 based on Phase 2 data with a 55% probability of success. We’re modeling the highest sales of $ 533 million in 2032, ”said Raja. “The CNS pipeline also includes WP1244 (the new DNA binding agent), which is 500 times more potent than daunorubicin at inhibiting tumor cell proliferation. It is expected to enter the clinic in 2021 … the next antitumor activity,” added the analyst. He rates CNSP on Buy, and his price target of $ 10 means room for a dramatic increase potential of 350% over the next 12 months. (Click here to view Raja’s past performance) What will the rest of the street say? Buy and Hold 1 are added to a Strong Buy consensus rating.Given an average price target of $ 8.33, shares could increase by ~ 275% next year. (See CNSP stock analysis on TipRanks) aTyr Pharma (LIFE) The next stock we look at is aTyr Pharma focuses on inflammatory disease Leading drug candidate ATYR1923 is a Neuropilin-2 (NRP2) agonist that works through receptor proteins expressed by the NRP2 gene. It is important for ulcer development and disease and plays a role in inflammatory lung disease pulmonary sarcoidosis. In December, the company reported that the drug candidate had completed registration of 36 patients in a Phase 1b / 2a clinical trial and tested the drug for the treatment of pulmonary sarcoidosis. The results of the current study are expected to be in 3Q21 and will inform further trials of ATYR1923, including those against other forms of inflammatory lung disease. On a more pressing note, the company announced the top-tier results of another Phase 2 clinic involving ATRY1923 in early January – this time for the treatment of patients hospitalized for severe respiratory complications from COVID-19. The results were positive and showed that a single dose of ATYR1923 (at 3 mg / kg) resulted in a median recovery time of 5.5 days. Overall, 83% of patients dosed this way saw improvement in less than a week. 5-star analyst Zegbeh Jallah told LIFE for Roth Capital, “We love the risk profile here with two hits on target, and updated data details from the COVID study are expected in the coming months. It was also recently announced that data from aTyr’s Pulmonary Sarcoidosis program will be reported in Q3 … The success of any of these studies could result in a doubling of market value or more, as these opportunities appear to be barely accounted for by investors. “In keeping with his optimistic approach, Jallah gives LIFE shares a Buy rating and the $ 15 price target shows an impressive 277% potential increase for the next year. (Click here to view Jallah’s past performance) Other analysts on the same page. With the buy rating, the word on the street is LIFE is a Strong Buy. In addition, the average price target is $ 13.33, indicating strong growth of ~ 236% from the current price of $ 3.97 (see LIFE stock analysis at TipRanks. ) To find good ideas for trading penny stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that combines all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are only prominent. The content is intended for informational use only. Your own analysis before making any investment. It is very important that you do business.